111 related articles for article (PubMed ID: 18388870)
1. Inflammation and altered drug clearance in cancer: transcriptional repression of a human CYP3A4 transgene in tumor-bearing mice.
Robertson GR; Liddle C; Clarke SJ
Clin Pharmacol Ther; 2008 Jun; 83(6):894-7. PubMed ID: 18388870
[TBL] [Abstract][Full Text] [Related]
2. Use of transgenic mouse models to understand the oral disposition and drug-drug interaction potential of cobimetinib, a MEK inhibitor.
Choo EF; Woolsey S; DeMent K; Ly J; Messick K; Qin A; Takahashi R
Drug Metab Dispos; 2015 Jun; 43(6):864-9. PubMed ID: 25813936
[TBL] [Abstract][Full Text] [Related]
3. Transcriptional repression of hepatic cytochrome P450 3A4 gene in the presence of cancer.
Charles KA; Rivory LP; Brown SL; Liddle C; Clarke SJ; Robertson GR
Clin Cancer Res; 2006 Dec; 12(24):7492-7. PubMed ID: 17189422
[TBL] [Abstract][Full Text] [Related]
4. Inhibition and stimulation of intestinal and hepatic CYP3A activity: studies in humanized CYP3A4 transgenic mice using triazolam.
van Waterschoot RA; Rooswinkel RW; Sparidans RW; van Herwaarden AE; Beijnen JH; Schinkel AH
Drug Metab Dispos; 2009 Dec; 37(12):2305-13. PubMed ID: 19752211
[TBL] [Abstract][Full Text] [Related]
5. Inflammation and CYP3A4-mediated drug metabolism in advanced cancer: impact and implications for chemotherapeutic drug dosing.
Kacevska M; Robertson GR; Clarke SJ; Liddle C
Expert Opin Drug Metab Toxicol; 2008 Feb; 4(2):137-49. PubMed ID: 18248309
[TBL] [Abstract][Full Text] [Related]
6. Extrahepatic cancer suppresses nuclear receptor-regulated drug metabolism.
Kacevska M; Downes MR; Sharma R; Evans RM; Clarke SJ; Liddle C; Robertson GR
Clin Cancer Res; 2011 May; 17(10):3170-80. PubMed ID: 21498392
[TBL] [Abstract][Full Text] [Related]
7. In Vitro Approaches to Study Regulation of Hepatic Cytochrome P450 (CYP) 3A Expression by Paclitaxel and Rifampicin.
Ghose R; Mallick P; Taneja G; Chu C; Moorthy B
Methods Mol Biol; 2016; 1395():55-68. PubMed ID: 26910068
[TBL] [Abstract][Full Text] [Related]
8. Autoinhibition of CYP3A4 leads to important role of CYP2C8 in imatinib metabolism: variability in CYP2C8 activity may alter plasma concentrations and response.
Filppula AM; Neuvonen M; Laitila J; Neuvonen PJ; Backman JT
Drug Metab Dispos; 2013 Jan; 41(1):50-9. PubMed ID: 23028140
[TBL] [Abstract][Full Text] [Related]
9. 4β-hydroxycholesterol as an endogenous CYP3A marker in cancer patients treated with taxanes.
de Graan AJ; Sparreboom A; de Bruijn P; de Jonge E; van der Holt B; Wiemer EA; Verweij J; Mathijssen RH; van Schaik RH
Br J Clin Pharmacol; 2015 Sep; 80(3):560-8. PubMed ID: 26119961
[TBL] [Abstract][Full Text] [Related]
10. Human bone marrow niche chemoprotection mediated by cytochrome P450 enzymes.
Alonso S; Su M; Jones JW; Ganguly S; Kane MA; Jones RJ; Ghiaur G
Oncotarget; 2015 Jun; 6(17):14905-12. PubMed ID: 25915157
[TBL] [Abstract][Full Text] [Related]
11. CYP3A4-mediated pharmacokinetic interactions in cancer therapy.
Tian D; Hu Z
Curr Drug Metab; 2014; 15(8):808-17. PubMed ID: 25705904
[TBL] [Abstract][Full Text] [Related]
12. Extra-hepatic cancer represses hepatic drug metabolism via interleukin (IL)-6 signalling.
Kacevska M; Mahns A; Sharma R; Clarke SJ; Robertson GR; Liddle C
Pharm Res; 2013 Sep; 30(9):2270-8. PubMed ID: 23604979
[TBL] [Abstract][Full Text] [Related]
13. A Fibroblast Growth Factor 21-Pregnane X Receptor Pathway Downregulates Hepatic CYP3A4 in Nonalcoholic Fatty Liver Disease.
Woolsey SJ; Beaton MD; Mansell SE; Leon-Ponte M; Yu J; Pin CL; Adams PC; Kim RB; Tirona RG
Mol Pharmacol; 2016 Oct; 90(4):437-46. PubMed ID: 27482056
[TBL] [Abstract][Full Text] [Related]
14. A useful model capable of predicting the clearance of cytochrome 3A4 (CYP3A4) substrates in humans: validity of CYP3A4 transgenic mice lacking their own Cyp3a enzymes.
Mitsui T; Nemoto T; Miyake T; Nagao S; Ogawa K; Kato M; Ishigai M; Yamada H
Drug Metab Dispos; 2014 Sep; 42(9):1540-7. PubMed ID: 25005602
[TBL] [Abstract][Full Text] [Related]
15. Determination of a quantitative relationship between hepatic CYP3A5*1/*3 and CYP3A4 expression for use in the prediction of metabolic clearance in virtual populations.
Barter ZE; Perrett HF; Yeo KR; Allorge D; Lennard MS; Rostami-Hodjegan A
Biopharm Drug Dispos; 2010 Nov; 31(8-9):516-32. PubMed ID: 21104927
[TBL] [Abstract][Full Text] [Related]
16. Direct transcriptional regulation of human hepatic cytochrome P450 3A4 (CYP3A4) by peroxisome proliferator-activated receptor alpha (PPARα).
Thomas M; Burk O; Klumpp B; Kandel BA; Damm G; Weiss TS; Klein K; Schwab M; Zanger UM
Mol Pharmacol; 2013 Mar; 83(3):709-18. PubMed ID: 23295386
[TBL] [Abstract][Full Text] [Related]
17. Marsdenia tenacissima extract inhibits gefitinib metabolism in vitro by interfering with human hepatic CYP3A4 and CYP2D6 enzymes.
Han SY; Zhao HY; Zhou N; Zhou F; Li PP
J Ethnopharmacol; 2014; 151(1):210-7. PubMed ID: 24157377
[TBL] [Abstract][Full Text] [Related]
18. Impact of CYP3A4 haplotypes on irinotecan pharmacokinetics in Japanese cancer patients.
Sai K; Saito Y; Fukushima-Uesaka H; Kurose K; Kaniwa N; Kamatani N; Shirao K; Yamamoto N; Hamaguchi T; Kunitoh H; Ohe Y; Tamura T; Yamada Y; Minami H; Ohtsu A; Yoshida T; Saijo N; Sawada J
Cancer Chemother Pharmacol; 2008 Aug; 62(3):529-37. PubMed ID: 17992531
[TBL] [Abstract][Full Text] [Related]
19. Impact of cytochrome P450 3A4 inducer and inhibitor on the pharmacokinetics of trabectedin in patients with advanced malignancies: open-label, multicenter studies.
Machiels JP; Staddon A; Herremans C; Keung C; Bernard A; Phelps C; Khokhar NZ; Knoblauch R; Parekh TV; Dirix L; Sharma S
Cancer Chemother Pharmacol; 2014 Oct; 74(4):729-37. PubMed ID: 25100135
[TBL] [Abstract][Full Text] [Related]
20. A transgenic mouse model with a luciferase reporter for studying in vivo transcriptional regulation of the human CYP3A4 gene.
Zhang W; Purchio AF; Chen K; Wu J; Lu L; Coffee R; Contag PR; West DB
Drug Metab Dispos; 2003 Aug; 31(8):1054-64. PubMed ID: 12867495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
